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OBJECTIVES The goal of this study was to test the hypothesis that NCX-4016 may have broader
anti-inflammatory and antithrombotic effects as well as better gastric tolerability than aspirin
in humans.
BACKGROUND NCX-4016 is an aspirin derivative containing a nitric oxide-releasing moiety that prevents
platelet activation and modulates tissue factor (TF) expression and cytokine release from
lipopolysaccharide (LPS)-stimulated monocytes.
METHODS This was a blind-observer, placebo-controlled, parallel-group study in which 48 healthy
subjects were randomized to receive NCX-4016 800 mg twice a day, NCX-4016 800 mg
twice a day plus aspirin 325 mg, aspirin 325 mg, or placebo for 21 days.
RESULTS Similar to aspirin alone, NCX-4016 effectively inhibited platelet aggregation induced by 0.6
mmol/l arachidonic acid, clot-stimulated thromboxane (TX) B2 generation in whole blood,
and urinary excretion of 11-dehydro-TXB2. Unlike aspirin alone, the administration of
NCX-4016 significantly inhibited TF expression in monocytes stimulated ex vivo with 10
mol/l LPS (determined by flow-cytometry analysis of TF on CD14 positive cells).
NCX-4016 also inhibited the rapid TF expression induced in monocytes by a proteinase
activated receptor agonist (thrombin receptor activator protein, 2 mol/l) as well as
LPS-induced expression of CD11b . Ex vivo, release of MCP-1 and interleukin-6 were
significantly inhibited by NCX-4016, but not by aspirin. NCX-4016 was not associated with
gastric damage, and significantly reduced gastric injury when co-administered with aspirin,
although both drugs reduced gastric PGE2 production to the same extent.
CONCLUSIONS NCX-4016 is equally effective as aspirin in inhibiting cyclooxygenase activity. However,
NCX-4016 causes less gastric damage and prevents monocyte activation. Larger multicenter
trials are warranted to establish clinical efficacy and safety of NCX-4016. (J Am Coll
Cardiol 2004;44:635–41) © 2004 by the American College of Cardiology Foundationu
p
l
C
4
l
t
m
p
(
e
a
t
m
s
s
r
e
ACX-4016 (2-[acetyloxy]benzoic acid 3-[nitrooxy
ethyl]phenyl ester) is an acetylsalicylic acid (aspirin)
ASA) derivative containing a nitric oxide (NO)-releasing
oiety that has been investigated as an antithrombotic and
nti-inflammatory drug (1). NCX-4016 inhibits cyclooxy-
See page 642
enase (COX) activity in platelets both in vitro and ex vivo
nd, similar to ASA, prevents the release of thromboxane
TX) A2 and arachidonic acid-induced platelet aggregation
2–4). NCX-4016 has also been found to inhibit ASA-
nsensitive platelet aggregation as well as platelet adhesion
nd the expression of platelet adhesion molecules in vitro,
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Manuscript received January 30, 2004; revised manuscript received February 27,i004, accepted March 2, 2004.nlike its parent compound (1). These activities were
revented by the use of NO scavengers, indicating that at
east part of the antiplatelet activity of NCX-4016 is
OX-independent and mediated by NO (2).
We hypothesized that, in comparison with ASA, NCX-
016 might have anti-inflammatory activities that are re-
ated to its antithrombotic effects as inflammation and
hrombosis are tightly linked (5,6). Tissue factor (TF) is the
ajor determinant of thrombogenicity of atherosclerotic
laques (7–9). Monocytes expressing TF and MAC-1
CD11b) and proinflammatory cytokines and chemokines
xert a mechanistic role in the complex choreography of
therothrombosis ranging from the induction of a pro-
hrombotic phenotype in endothelial cells to the recruit-
ent of leukocytes and the generation of unstable athero-
clerotic plaques (6,10).
While investigating the effect of NCX-4016 in lipopoly-
accharide (LPS)-stimulated human monocytes, we found a
eduction in the cellular release of cytokines as well as the
xpression of TF in response to NCX-4016, but not with
SA (11,12). Similarly, in a rodent model of inflammation,n vivo administration of NCX-4016, but not ASA, de-
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Effects of NCX-4016 in Humans August 4, 2004:635–41reased TF expression and activity on circulating monocytes
13), suggesting that this compound exerts NO-mediated,
SA-independent, anti-inflammatory activities.
The present study evaluated whether administration of
CX-4016 prevents activation of both platelets and mono-
ytes and also assessed its gastric tolerability. NCX-4016
as given to healthy subjects for a prolonged period of time
nd compared with ASA, administered alone or in associ-
tion with NCX-4016. By using proteinase activated recep-
or (PAR)-1 agonist and LPS as stimuli, we also explored
he mechanism by which NCX-4016 modulates TF expres-
ion. Finally, by examining the combined effects of NCX-
016 and ASA on gastric mucosa and platelet and monocyte
unctions, we demonstrated an increased gastric tolerability
nd potential antithrombotic effects of NCX-4016.
ETHODS
ubjects. Forty-eight healthy subjects (32 men and 16
omen; range, 19 to 44 years) were enrolled. Exclusion
riteria were: gastrointestinal symptoms; alcohol or drug
buse; pregnancy; intolerance or hypersensitivity to ASA; a
istory of liver, kidney, or cardiac disease; peptic ulceration;
r upper digestive tract surgery. Subjects were also excluded
f they had received any medication in the three weeks
efore the study, including herbal remedies. Subjects were
xcluded if they had abnormal findings on baseline endos-
opy (total endoscopic score 1) or an abnormal baseline
iochemical profile. A serum sample from each subject was
nalyzed for the presence of IgG antibodies to Helicobacter
ylori (EIAgen kit, Biochem Immunosystem, Bologna,
taly).
tudy design. This was a blind-observer, parallel-group
tudy in which subjects were randomized into four groups
omposed of 12 subjects each that received one of the
ollowing treatments: 1) NCX-4016 placebo twice daily; 2)
CX-4016 800 mg twice daily; 3) NCX-4016 800 mg
wice daily plus commercial ASA 325 mg once daily; 4)
ommercial ASA 325 mg once daily plus NCX-4016
lacebo once daily. Randomization was performed in blocks
f four from a computer-generated list. The medications
ere taken orally at 8 AM and 8 PM at the clinical site for 21
onsecutive days. On the mornings of the first (day 0) and
he last day of the study (day 22), approximately 12 h after
Abbreviations and Acronyms
ASA  aspirin/acetylsalicylic acid
COX  cyclooxygenase
IL  interleukin
LPS  lipopolysaccharide
NO  nitric oxide
PAR  proteinase activated receptor
TF  tissue factor
TRAP  thrombin receptor activator protein
TX  thromboxanehe last drug administration, endoscopic examination was serformed. Systolic and diastolic blood pressures were
easured in the supine and standing position before, 1, 3,
nd 6 h after drug administration. Heart rate was also
ecorded. Blood samples were collected immediately before
nd 4 h after drug administration for basal and post-
reatment biochemical analyses, platelet aggregation and
erum TXB2 studies. The urinary excretion of 11-dh-TXB2
as assessed on days 0 and 21 (6-h urine collections, from
AM to 1 PM). Tissue factor expression on blood monocytes
nd the ex vivo release of MCP-1 and interleukin (IL)-6
ere determined on day 21, 4 h after the last drug
dministration. The study was approved by local ethics
ommittee, and written informed consent was obtained
rom all subjects.
latelet aggregation. Platelet aggregation was assayed ac-
ording to Born’s turbidimetric method using a 4-channel
ggregometer (APACT4, Helena Biosciences Europe, Sun-
erland, United Kingdom). Blood was collected and anti-
oagulated with 3.8% sodium citrate, and platelet-rich
lasma was obtained by centrifugation at 200  g for 10
in. Platelet-rich plasma was incubated for 3 min at 37°C,
nd one of the following agonists was then added: arachi-
onic acid (0.6 mmol/l), the PAR-1 agonist SFLLRNPND-
YEPF (thrombin receptor activator peptide [TRAP], Sigma
hemical Co., St. Louis, Missouri; 10 mol/l), the TXA2
nalogue U46619 (1.5 mol/l). The percentage of aggrega-
ion was determined 3 min after the addition of platelet
gonists.
astroduodenal endoscopy and mucosal biopsies. Upper
ndoscopies were performed using an Olympus Exera GIF-
160 apparatus (Olympus Europe, Hamburg, Germany).
he entire stomach and duodenum were systematically
xamined from the fundus to the duodenum. Endoscopies
ere evaluated by an independent gastroenterologist and by
medical advisor for gastroscopy under blind conditions.
ach endoscopic procedure was completely recorded using a
HS recorder. Mucosal lesions were graded according to a
odified Lanza’s scale: grade 0  normal mucosa; grade
 1 to 3 erosions or submucosal hemorrhages; grade 2 
to 10 erosions or submucosal hemorrhages; grade 3 
10 erosions or submucosal hemorrhages; grade 4  ulcer
r diffuse submucosal hemorrhages. Separate endoscopic
njury scores were assigned for the esophagus, gastric fun-
us, gastric body, gastric antrum, and duodenum (4).
At the end of endoscopic evaluation, four biopsies were
aken from the antrum. Biopsy specimens were frozen in
iquid nitrogen and then added to a tube containing 100%
thanol plus 0.1 mmol/l indomethacin and were homoge-
ized and centrifuged for 10 min at 12,000 rpm at 4°C. The
upernatant of each sample was analyzed for the amount of
GE2 and PGF2, major prostaglandins synthesized in the
uman gastric mucosa, using commercial enzymatic immu-
oassay (EIA) kit (PGE2 and PGF2 EIA kits, Cayman
hemical Co., Ann Arbor, Michigan).
erum TXB2. For the measurement of serum TXB2, the
table non-enzymatic metabolite of TXA2, 5 ml of venous
n
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August 4, 2004:635–41 Effects of NCX-4016 in Humanson-anticoagulated blood samples were allowed to clot for
h at 37°C in glass tubes and then centrifuged at 3,000 g for
5 min. Serum samples were then stored at 80°C until
ssayed by EIA (Cayman Chemical Co.).
rinary TXA2-metabolite excretion. Urine samples (40
l) were centrifuged and stored at 20°C until chro-
atographic purification procedures were performed.
1-dehydro-TXB2, the major TXA2 metabolite in urine,
as then measured by EIA using a specific monoclonal
ntibody (Cayman Chemical Co.).
low-cytometry analysis of TF expression. Blood sam-
les (3 ml) were collected using either sodium citrate or
odium heparin as anticoagulants; TRAP (2 mol/l) was
dded to citrate-anticoagulated blood samples, which
ere then incubated for 15 min at 37°C. Bacterial LPS
Escherichia coli, O113:H10, Sigma Chemical Co.) was
dded to heparin-anticoagulated blood samples and in-
ubated for 6 h. After incubation with agonists, blood
amples were diluted in lysis buffer for red cells (155
mol/l NH4Cl, 10 mmol/l KHCO3, and 0.1 mmol/l
DTA). White blood cells were then incubated with
nti-CD14 PC5-conjugated monoclonal antibody for 30
in at 4°C (Beckman Coulter, Fullerton, California),
ashed, and stained with goat anti-human FITC-
onjugated anti-TF monoclonal antibody (American Di-
gnostica, Stamford, Connecticut) for 30 min at 4°C. For
D11b staining, cells were incubated with FITC-
onjugated goat anti-human CD11b monoclonal anti-
ody (Beckman Coulter). Freshly stained cells were
nalyzed by double-color fluorescence distribution on an
PIX XL cytofluorimeter (Beckman Coulter) and the
umber of CD14-TF positive cells counted; the mean
ntensity of florescence was also calculated.
CP-1 and IL-6 secretion. Plasma obtained from heparin-
nticoagulated and LPS-stimulated blood samples was as-
ayed for MCP-1 and IL-6 concentration using specific
nzyme immunoassays (Endogen Pierce Biotechnology,
ockford, Illinois).
tatistical analysis. The calculation of the sample size and
ower for the analysis of variance (ANOVA) with contrasts,
as made with PASS 2002 software (NCSS Statistical
oftware, Kaysville, Utah). The total sample of 48 subjects
chieves about 85% power to detect a difference of at least
in the mucosal damage scores. The common SD within a
roup was assumed to be 2. An alpha level of 0.05 was
sed for all statistical tests. Data were analyzed using the
AS/STAT version 8.2 (SAS Institute Inc., Cary, North
arolina). The primary objectives of the study were to
ompare the mucosal damage scores, platelet aggregation,
nd TXB2 at day 21. Differences between treatment groups
ere tested using the ANOVA followed by Tukey-Kramer
est for pairwise multiple comparisons. Values of p  0.05
ere considered significant. Data are expressed as mean 
E. 4ESULTS
ll volunteers completed the study protocol. There were no
tatistically significant differences between the basal and
nd-of-treatment hematic-biochemical values in any of the
our groups (data not shown). No statistically significant
ifferences in supine and standing blood pressure or heart
ate were observed between subjects receiving placebo or any
f the active treatments at baseline or at days 1, 7, and 21
data not shown). Serum IgG antibodies to H. pylori were
ound in 23 subjects: 6 in the placebo group, 6 in the
SA-treated group, 4 in the NCX-4016–treated group,
nd 7 in NCX-4016 plus ASA group (p not significant
mong groups).
ffect of ASA and NCX-4016 on gastrointestinal mucosa.
o visible injury was present in either the stomach or
uodenum in any of the 48 participants at baseline. As
hown in Figure 1A, three weeks administration of ASA
25 mg once daily resulted in appearance of gastric and/or
uodenal lesions with a mean total endoscopic score of 13.3
2.1 (p  0.0001 vs. placebo). Administration of 800 mg
wice a day NCX-4016 caused only minimal gastrointestinal
njury, similar to that observed in the placebo group, with a
ean total endoscopic score of 1.8  0.5 (1.7  0.7 in the
lacebo group; p  0.0001 vs. ASA). Co-administration of
CX-4016 and ASA attenuated the gastroduodenal dam-
ge caused by ASA, resulting in a mean endoscopic score of
.8  0.8 (p  0.001 vs. ASA). Administration of NCX-
igure 1. Effect of NCX-4016 and aspirin (ASA) on gastric mucosa as
valuated by endoscopy after the administration of NCX-4016, ASA, or
oth drugs for 21 days (A). NCX-4016 administration was associated with
ess extended gastric damage, compared with aspirin alone, as assessed
sing a modified Lanza’s score. Both aspirin and NCX-4016 reduced the
ontent of prostaglandins E2 (PGE2) and F2 (PGF2) in the gastric
ucosa (B). Means and standard errors, n  12; *p  0.001 vs. placebo;
*p  0.001 vs. ASA alone.016 and the combination of the two caused an 80%
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Effects of NCX-4016 in Humans August 4, 2004:635–41eduction in gastric PGE2 and PGF2 concentrations (Fig.
B) (p  0.001 vs. placebo).
ffect of ASA and NCX-4016 on platelet aggregation. No
ifferences in arachidonic acid-induced aggregation were
bserved among treatment groups under basal conditions.
latelet aggregation was not induced in subjects admin-
stered NCX-4016, ASA, or both drugs for 21 days,
ither immediately before or 4 h after the last drug
dministration (Fig. 2A). Aggregation induced by
hrombin or U46619 was not affected by any treatment
data not shown).
ffect of ASA and NCX-4016 on serum TXB2 and
XA2-metabolite excretion. Both ASA and NCX-4016
educed the serum concentrations of TXB2 by more than
0% (p  0.0001 vs. placebo), although ASA was more
ffective (p  0.001 vs. NCX-4016). Co-administration of
CX-4016 and ASA did not interfere with the antiplatelet
ctivity of the latter drug (Fig. 2B). Aspirin and NCX-4016
igure 2. Platelet aggregation induced by 0.6 mmol/l arachidonic acid was
ompletely inhibited by prolonged administration of NCX-4016, aspirin
ASA), and NCX-4026 plus ASA (A). This was accompanied by a
tatistically significant reduction in the serum concentration of thrombox-
ne (TX) B2, index of cyclooxygenase activity in platelets (B), and urinary
xcretion of 11-dehydro(dh)-TXB2, index of in vivo TXA2 biosynthesis
C). Means and standard errors, n  12; *p  0.0001 vs. placebo.ere also equally effective in reducing the urinary excretion ef 11-dehydro-TXB2 (Fig. 2C). Again, co-administration
f NCX-4016 and ASA did not affect the inhibitory activity
f either drug.
ffect of ASA and NCX-4016 on TF expression and
ytokine/chemokine generation in ex vivo-stimulated
onocytes. As illustrated in Figure 3, treatment of
D14 cells with TRAP and LPS resulted in a significant
pregulation of TF expression, as measured by assessing the
ercent of TF-positive monocytes (Figs. 3A and 3B) and
ean intensity fluorescence (Figs. 3C and 3D, n  12, p 
.01 vs. untreated cells). Administration of NCX-4016
esulted in significant attenuation of ex vivo upregulation of
F induced by either TRAP or LPS (p 0.05 vs. agonists).
CX-4016 also maintained this effect when co-
dministered in combination with ASA. However, ASA
lone failed to modulate the expression of TF.
Ex vivo exposure of CD14-positive cells to LPS resulted
n significant upregulation of both MCP-1 and IL-6 (Figs.
A and 4B, p  0.01 vs. untreated). Lipopolysaccharide
timulation of blood samples obtained from volunteers
reated with NCX-4016 resulted in a 50% reduction of
CP-1 and a 25% reduction of IL-6 (p  0.05 vs. placebo
nd ASA). This effect was maintained in volunteers treated
ith NCX-4016 plus ASA (p  0.05 vs. placebo and ASA
lone), but not in volunteers treated with ASA alone,
ndicating that the NO-releasing moiety of NCX-4016 was
ikely responsible for these effects. Administration of NCX-
016 resulted in significant reduction of CD11b expression
n CD14-positive cells (Figs. 4C and 4D) (p  0.05 vs.
lacebo). Moreover, this effect was maintained in volunteers
dministered with NCX-4016 in combination with ASA,
hile ASA by itself was ineffective (Figs. 4C and 4D).
ISCUSSION
CX-4016 contains two pharmacologically active moieties,
amely an ASA-like moiety and a NO-releasing moiety,
hich both contribute to its pharmacologic effects. In fact,
his compound has dual pharmacodynamic effects, acting as
COX inhibitor and a NO donor. In the present study, we
xplored the capacity of NCX-4016 to reduce the genera-
ion of TXA2 in platelets by acting as a COX inhibitor. This
as been previously shown in vitro and ex vivo both in
xperimental animals and humans by testing the release of
XB2 from aggregating platelets induced by blood coagu-
ation (1,2,4). Herein, we demonstrate that both NCX-
016 and ASA reduce the clot-stimulated TXB2 release
rom aggregating platelets by more than 90%. This inhibi-
ory effect is associated with both the prevention of arachi-
onic acid-induced platelet aggregation and substantial
eduction in the urinary excretion of 11-dehydro-TXB2,
hus suggesting that NCX-4016 satisfies the requirement of
sustained inhibition in a platelet synthetic capacity that
as shown to be necessary for a COX inhibitor in order to
revent in vivo platelet activation (14,15). The urinary
xcretion of 11-dehydro-TXB2 represents a reliable index of
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August 4, 2004:635–41 Effects of NCX-4016 in Humansn vivo platelet activation and predicts adverse cardiovascular
vents in high-risk patients (16). Oral administration of
SA to healthy subjects reduces the urinary excretion of
1-dehydro-TXB2 by about 80%. Extraplatelet sources may
ccount for the residual excretion of 11-dehydro-TXB2,
hich increases under clinical and experimental conditions
elated to atherothrombosis due to the contribution of
OX-2-expressing inflammatory cells (17). Although
CX-4016 has been shown to inhibit both platelet COX-1
ctivity and COX-2 expression in monocytes (13), we may
nfer that platelet COX is the target of both drugs in healthy
ubjects, because no additive effect on the urinary excretion
f 11-dehydro-TXB2 is observed when NCX-4016 and
SA were co-administered. The present results are consis-
ent with the previous demonstration that ASA is actually
eleased in vivo from NCX-4016 and is, furthermore,
esponsible for its ASA-like activity (18).
If both ASA and NCX-4016 effectively inhibit platelet
OX, the antithrombotic activity of both drugs should be
xpected to be similar. However, previous data indicate that
CX-4016 is superior to ASA in an animal model of
latelet-mediated pulmonary embolism (19), suggesting
hat NCX-4016 has in vivo COX-independent, NO-
ediated properties that are not shared by ASA, such as the
nti-adhesive effects shown in vitro (2). Consistent with this
iew, we have previously shown that NCX-4016, but not
igure 3. Tissue factor (TF) expression in monocytes (CD14 cells) was i
A and B) or 10 mmol/l lipopolysaccharide (LPS) (C and D). The admin
ASA) reduced TF expression compared with placebo and ASA alone, as
uorescence intensity (MIF). n  12. *p  0.05 LPS or TRAP vs. untreat
SA vs. ASA alone.SA, inhibits TF expression on LPS-stimulated monocytes11,12). Both synthesis and expression of TF, as well as
F-dependent procoagulant activity and TXA2 biosynthe-
is, were reduced by NCX-4016, further supporting the
oncept that both COX-dependent and -independent
echanisms are responsible for the action of this drug
13,20). Therefore, we tested the hypothesis that NCX-
016 has effects on monocyte function in humans by
nvestigating its effects on TF expression.
Tissue factor expression induced by LPS occurs primarily
ia gene transcription and is a delayed effect (21). Experi-
ental evidence supports the hypothesis that NO is respon-
ible for downregulation of TF expression acting on protein
ynthesis (22). However, when NCX-4016 and nitrosorbide
ononitrate was tested in LPS-challenged animals, the
xpression of TF on monocytes was also downregulated in
he absence of a reduction in TF messenger RNA and
rotein synthesis, suggesting that NO can also modulate TF
xpression by altering its intracellular traffic by reducing the
ssembly of preformed TF on the outer side of the cell
embrane (13). The data from the present study give
dditional weight to this hypothesis (13,22), and, in fact, we
ave demonstrated that surface expression of TF on mono-
ytes can be induced within minutes via stimulation of
AR-1 without requiring messenger RNA synthesis (23);
nlike ASA, NCX-4016 almost completely prevents PAR-
-mediated surface expression of TF.
d ex vivo by either 2 mmol/l thrombin receptor activator protein (TRAP)
ion of NCX-4016 either alone or in combination with acetylsalicylic acid
sed by flow-cytometry and measuring the percentage of positive cells and
lls; **p  0.05 NCX-4016 vs. LPS or TRAP; p  0.05 NCX-4016 andnduce
istrat
asses
ed ceWhile direct modulation of TF expression on CD14
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Effects of NCX-4016 in Humans August 4, 2004:635–41ells might well explain the effect of NCX-4016, there is
vidence that TF expression is amplified by the interaction
f platelets with monocytes (23,24). This interaction re-
uires the ligation of platelet P selectin and the release of
oluble factors (25). Because PAR-1 is expressed on both
latelets and monocytes and NCX-4016 acts on both cell
ypes, it cannot be excluded that TRAP-induced monocyte
ctivation is also modulated by the antiplatelet activities of
CX-4016 (2).
Another important observation of this study is the dem-
nstration that IL-6 and MCP-1 secretion as well as
D-11b expression on circulating monocytes was reduced
n subjects receiving NCX-4016, which may be of interest
hen the role of inflammation in vascular disease is consid-
red. Interleukin-6 and MCP-1 are known amplifiers of
therogenic changes and restenosis by inducing the migra-
ion of circulating monocytes and activating resident mono-
ytes/macrophages and by promoting changes in endothelial
nd smooth muscle cells (26,27). Because MCP-1 is a
timulus for TF expression on smooth muscle cells (28), it
ight be hypothesized that NCX-4016 is able to interrupt
he amplificatory loops in the inflammatory/thrombotic
rocess centered on TF expression. None of these anti-
nflammatory effects is observed with ASA unless NCX-
016 is co-administered. Along these lines, the NO-
ediated inhibition of transcription factors involved in the
nflammatory response might explain the multiple anti-
nflammatory effects shown by NCX-4106 in animals
igure 4. The administration of NCX-4016 either alone or in combina
rotein-1 (MCP-1) (A), interleukin-6 (IL-6) (B), and expression of CD1
lacebo and ASA alone.29,30). However, post-translational regulation of the aroinflammatory machinery could also be involved, because
CX-4016 has already been shown able to modulate IL-1
elease, through a NO-mediated inhibition of caspase-1
nterleukin converting enzyme activity (12).
Several lines of evidence indicate that the administration
f NCX-4016 is associated with less gastric damage than
SA (4). The gastric tolerability of NCX-4016 (800 mg
wice a day) has already been shown to be superior to that of
SA (100 mg once a day) (31). We extended this concept
y demonstrating that the severity of gastric damage caused
y a common daily dose of 325 mg ASA is reduced when
dministered together with NCX-4016. Similar to ASA,
dministration of NCX-4016 resulted in near complete
nhibition of gastric PGE2, suggesting that NO has the
bility to compensate for the reduced generation of gastric
rostanoids (31,32). This observation might be of relevance
hen multiple antiplatelet drugs, with potential gastric
oxicity, are co-administered to prevent restenosis to pa-
ients that underwent coronary or carotid angioplasty. Low
oses of ASA (i.e., 100 mg/day or less) and clopidogrel are
urrently used to minimize gastric toxicity, and are similarly
ffective and tolerable (33). At present, no studies have yet
ompared NCX-4016 and clopidogrel in terms of efficacy
nd gastric tolerability. However, the data from the present
tudy permit the speculation that NCX-4016 may be at least
s tolerable as clopidogrel.
Finally, NCX-4016 does not induce in humans any
ignificant change in blood pressure and heart rate, in
with aspirin (ASA) reduced the secretion of monocyte chemoattractant
and D) compared with placebo and ASA alone. n  12. *p  0.05 vs.tion
1b (Cgreement with previous observations and with the notion
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August 4, 2004:635–41 Effects of NCX-4016 in Humanshat NO is slowly released from the molecule (P. del
oldato, personal communication, June 2003).
In conclusion, the results of the present study indicate
hat NCX-4016 exhibits a broader spectrum of activities
han ASA and that NCX-4016 induces less gastric damage
lso when administered in combination with the former.
his study is the first demonstration that a NO-donor and
OX inhibitor downregulates TF as well as IL-6 and
CP-1 in humans. These beneficial effects of NCX-4016,
ombined with the inhibition of TXA2, support the notion
hat NCX-4016 exerts multiple regulatory activities at the
onocyte/platelet interface and may be of relevance in the
linical setting of atherothrombotic diseases and restenosis
fter angioplasty, where TF expression and platelet-
onocyte interactions together with increased generation of
XA2 are observed (1,6). Larger multicenter clinical trials
re warranted in order to establish the clinical efficacy and
afety of NCX4016.
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